Landscapes / Companies

Coherus Oncology, Inc. not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
Approved
Next date
Toripalimab, Phase 2 trial completes
Drugs
5
in active trials · 9 in all
Trials
6 active
11 since 2021

Drugs5

DrugHow it worksPartnerStageNext dateDetails
Programmed death receptor-1 blocking antibody
Approved Sep 2027Phase 2 trial completes
Unmodified immunoglobulin
Phase 2 Sep 2027Phase 2 trial completes
Pasritamignot checked
Multi-specific immunoglobulin
Phase 1/2 Aug 2028Phase 1/2 trial completes
Tagmokitugnot checked
Unmodified immunoglobulin
Phase 1/2 Aug 2028Phase 1/2 trial completes
—
Phase 1 30 May 2028Phase 1 trial completes

About

No active trial
CHS-006, etrumadenant, SRF617, zimberelimab
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Coherus Oncology, Inc.

Following is part of Solo: you see every change to Coherus Oncology, Inc. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in